Seroatlas · Human Serome Atlas

LILRA6

Leukocyte immunoglobulin-like receptor subfamily A member 6

Also known as: CD85b, ILT8, LILRB6, LIRA6_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6PI73
Gene: LILRA6
Ensembl: ENSG00000244482
Chromosome: 19
Canonical length: 481 aa
Protein class: Predicted membrane proteins
Subcellular location: Plasma membrane,Cytosol

OverviewNCBI Gene

Predicted to enable inhibitory MHC class I receptor activity. Predicted to be involved in cytokine-mediated signaling pathway and immune response-regulating signaling pathway. Predicted to be located in membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

481 residues, UniProt reviewed canonical sequence.

>Q6PI73|LILRA6
     1  MTPALTALLC LGLSLGPRTR VQAGPFPKPT LWAEPGSVIS WGSPVTIWCQ GSLEAQEYQL
    61  DKEGSPEPLD RNNPLEPKNK ARFSIPSMTQ HHAGRYRCHY YSSAGWSEPS DPLELVMTGF
   121  YNKPTLSALP SPVVASGGNM TLRCGSQKGY HHFVLMKEGE HQLPRTLDSQ QLHSGGFQAL
   181  FPVGPVTPSH RWRFTCYYYY TNTPRVWSHP SDPLEILPSG VSRKPSLLTL QGPVLAPGQS
   241  LTLQCGSDVG YDRFVLYKEG ERDFLQRPGQ QPQAGLSQAN FTLGPVSPSH GGQYRCYGAH
   301  NLSSEWSAPS DPLNILMAGQ IYDTVSLSAQ PGPTVASGEN VTLLCQSRGY FDTFLLTKEG
   361  AAHPPLRLRS MYGAHKYQAE FPMSPVTSAH AGTYRCYGSY SSNPHLLSFP SEPLELMVSG
   421  HSGGSSLPPT GPPSTPASHA KDYTVENLIR MGMAGLVLVF LGILLFEAQH SQRNPQDAAG
   481  R

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LILRA6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 16 nTPM

Expression across tissuesHPA

Tissue

spleen: 16 nTPM
lung: 8.6 nTPM
adipose tissue: 3.1 nTPM
blood vessel: 1.9 nTPM
bone marrow: 1.6 nTPM
appendix: 1.5 nTPM

Single-cell type

monocytes: 3.2 nCPM
neutrophils: 2 nCPM
macrophages: 1 nCPM
cdc: 0.7 nCPM
microglia: 0.6 nCPM
monocyte progenitors: 0.3 nCPM

Immune cell

neutrophil: 8.4 nTPM
intermediate monocyte: 3.9 nTPM
classical monocyte: 3.5 nTPM
non-classical monocyte: 0.9 nTPM
total PBMC: 0.9 nTPM
myeloid DC: 0.2 nTPM

Brain region

thalamus: 0.4 nTPM
cerebral cortex: 0.2 nTPM
white matter: 0.2 nTPM
choroid plexus: 0.1 nTPM
pons: 0.1 nTPM
amygdala: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.91
gnomAD pLI: 0
gnomAD missense Z: -0.43

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

inhibitory MHC class I receptor activity

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LILRA6 as an antibody target. Whether an autoantibody or antibody against LILRA6 could matter depends on whether native LILRA6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LILRA6 is annotated at the cell surface, where native LILRA6 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LILRA6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...